Sign In
Buy ZLAB
$17.17
+0.0200 (+0.117%)
At Close: Jun 03, 2026
SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that China's National Medical Products Administration (NMPA) has approved the supplemental New
Zai Lab to Present at 44th Annual J.P. Morgan Healthcare Conference
07:30am, Monday, 05'th Jan 2026
SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that members of the Company's senior management team will participate in the 44th Annual J.P. M
Zai Lab (NASDAQ:ZLAB) Insider Rafael Amado Sells 10,787 Shares
05:38am, Saturday, 03'rd Jan 2026
Zai Lab Limited Unsponsored ADR (NASDAQ: ZLAB - Get Free Report) insider Rafael Amado sold 10,787 shares of Zai Lab stock in a transaction dated Wednesday, December 31st. The shares were sold at an av
Zai Lab Announces Approval of COBENFY (xanomeline and trospium chloride) in China, a First-in-Class Therapy for Schizophrenia
07:30am, Tuesday, 23'rd Dec 2025
SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that China's National Medical Products Administration (NMPA) approved the New Drug Application
SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced the dosing of the first participant in a global Phase 1/1b clinical trial evaluating the safety
Zai Lab Announces Updates to China's National Reimbursement Drug List
12:11am, Sunday, 07'th Dec 2025
SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that the following medicines and indications have been renewed in the 2025 National Reimburseme
Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) Receives $56.35 Average Target Price from Brokerages
02:10am, Sunday, 30'th Nov 2025
Zai Lab Limited Unsponsored ADR (NASDAQ: ZLAB - Get Free Report) has been given an average recommendation of "Moderate Buy" by the eight analysts that are presently covering the stock, Marketbeat repo
Zai Lab Limited: Declining Despite Making Progress - I See Opportunity (Reiterate Buy)
12:00pm, Tuesday, 11'th Nov 2025
ZLAB is continuing to grow revenues through its Chinese in-licensed strategy. Continuing growth of in-licensed programs is mixed, with imminent approvals in China but also termination of key studies.
Zai Lab Limited (ZLAB) Q3 2025 Earnings Call Transcript
08:16am, Friday, 07'th Nov 2025
Zai Lab Limited ( ZLAB ) Q3 2025 Earnings Call November 6, 2025 8:00 AM EST Company Participants Christine Chiou - Senior VP & Head of Investor Relations Ying Du - Founder, Chairperson & CEO Rafael Am
Zai Lab Announces Third Quarter 2025 Financial Results and Recent Corporate Updates
07:00am, Thursday, 06'th Nov 2025
SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced financial results for the third quarter of 2025, along with recent product highlights and corpo
Zai Lab Announces Participation in Investor Conferences in November and December 2025
07:30am, Friday, 31'st Oct 2025
SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that members of the Company's senior management team will participate in the following investor
Zai Lab Limited (NASDAQ:ZLAB ) Discusses Updated Monotherapy Phase I Data for Suzhou and Outlines Next Steps in Clinical Development October 24, 2025 11:00 AM EDT Company Participants Rafael Amado - P
SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced updated data from the global Phase 1 clinical trial of zocilurtatug pelitecan (zoci), formerly
Zai Lab to Announce Third Quarter 2025 Financial Results and Recent Corporate Updates on November 6, 2025
07:30am, Wednesday, 15'th Oct 2025
SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that it will report its third quarter 2025 financial results and provide recent corporate updat
SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that a late-breaking abstract (LBA) featuring new data from its global Phase 1 clinical trial (
